MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

12.94 +0.38 (+3.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Omeros Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside ↗
The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart. 
Via Stocktwits
News headline image
Hims & Hers, Salesforce, Omeros, United Airlines, And Sea Ltd: Why These 5 Stocks Are On Investors' Radars Today ↗
Major U.S. indices ended mixed on Wednesday, with the Dow Jones Industrial Average slipping 0.04% to 46,253.31. 
Via Benzinga
Topics Stocks
News headline image
The Terrific Ten Undercard: OMER, VERI, SNYR, MYSE, RDZN – Stocks Under $5 (Complete List Inside)
Via AB Newswire
Topics Artificial Intelligence Cannabis
News headline image
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal ↗
Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 billion and tiered royalties. 
Via Benzinga
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 14, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview: Omeros ↗
 
Via Benzinga
News headline image
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results ↗
 
Via Benzinga
News headline image
Omeros Rockets Skyward on $2.1 Billion Novo Nordisk Deal, Reshaping Biotech Landscape
In a dramatic turn of events that sent shockwaves through the biotechnology sector, Omeros Corporation (NASDAQ: OMER) witnessed its stock catapult by an astounding nearly 150% after announcing a... 
Via MarketMinute
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo Nordisk ↗
Novo Nordisk is licensing exclusive global rights to the company's experimental treatment for rare blood and kidney diseases. 
Via Investor's Business Daily
News headline image
Here are the top movers in Wednesday's session. ↗
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Gapping stocks in Wednesday's session ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday. 
Via Chartmill
News headline image
S&P 500 Gains 1%; Bank of America Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
From Omeros Corporation
Via Business Wire
News headline image
Omeros Posts 2,652 Percent Sales Jump ↗
Via The Motley Fool
News headline image
Omeros Corp (NASDAQ:OMER) Reports Q2 2025: Narrowed Losses, Regulatory Progress, and Market Optimism ↗
Omeros Corp (OMER) reports Q2 2025 with narrowed losses, progress on narsoplimab FDA approval, and strategic debt restructuring. Shares rise on regulatory optimism. 
Via Chartmill
News headline image
Omeros Corporation Reports Second Quarter 2025 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
From Omeros Corporation
Via Business Wire
InvestorNewsBreaks – D. Boral Capital LLC Acts as Exclusive Placement Agent for $22 Million Omeros (NASDAQ: OMER) Offering
Via Investor Brand Network
News headline image
D. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Direct Offering
Via ACCESS Newswire
News headline image
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering
From Omeros Corporation
Via Business Wire
News headline image
Omeros Seeks EMA Approval For Narsoplimab After Data Shows 3X Survival Boost ↗
The application includes outcomes from more than 130 patients treated under an expanded access program, supporting broader regulatory momentum for narsoplimab. 
Via Stocktwits
News headline image
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Webcast Details for Annual Meeting of Shareholders
From Omeros Corporation
Via Business Wire
News headline image
Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision ↗
H.C. Wainwright's Brandon Folkes initiated Omeros with a Buy. 
Via Benzinga
News headline image
This Domino's Pizza Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter ↗
 
Via Benzinga
News headline image
Omeros Corporation Reports First Quarter 2025 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Earnings Scheduled For May 15, 2025 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story